Advantar Labs moving to new site to build CRO relationships

- Last updated on GMT

Advantar Labs moving to new site to build CRO relationships
Advantar Laboratories is moving to a bigger facility in San Diego this week to expand its relationships with CROs.

The analytical development and formulation service provider will use the bigger facility, which covers 18,000 square foot in California, to develop its business with CROs (contract research organisations).

The larger facility will also allow for the development of new business relationships with a specific emphasis on collaborating with [preclinical and clinical CROs]​”, Advantar Labs said in a statement.

Advantar Labs is already working with other service providers. In September it inked a non-exclusive deal with DavosPharma, a provider of discovery, chemistry, and formulation services, to collaborate on helping biopharma clients.

As well as increasing emphasis on CROs, the site will allow Advantar Labs to grow its headcount and add business with manufacturers of finished products and active pharmaceutical ingredients (APIs).

We anticipate that the new facility will accommodate approximately 70 scientists and support staff. Strategically, this move will allow for continued growth, increased efficiency and overall lower costs for our operations​”, Richard Kenley, CEO of Advantar Labs, said.

The move to the new facility began last Thursday and Advantar Labs expects the new site to open for business on Monday. After completing the move Advantar Labs will have several positions to fill and is encouraging anyone who is interested to attend its open house event in May with their résumé.

Related news

Related products


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers